SCHEMBL4736885

SCHEMBL4736885

CCOc1cc(-c2ccccc2)ccc1COc1ccc([C@H](CC(=O)O)c2nnnn2C)cc1

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 18/20 0.56
CTSA P10619 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4738097 0.85 FFAR1 (0.62) FFAR1
SCHEMBL4742074 0.85 FFAR1 (0.62) FFAR1
SCHEMBL4767757 0.83 FFAR1 (0.59) FFAR1
SCHEMBL3550142 0.78 FFAR1 (0.75) FFAR1
SCHEMBL3550138 0.78 FFAR1 (0.75) FFAR1
SCHEMBL4739724 0.76 FFAR1 (0.61) FFAR1
SCHEMBL4739732 0.76 FFAR1 (0.61) FFAR1
SCHEMBL4737069 0.76 FFAR1 (0.70) FFAR1
SCHEMBL4736688 0.75 FFAR1 (0.67) FFAR1
SCHEMBL4681590 0.75 FFAR1 (0.67) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893582-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2008-03-05 EP claimed
WO-2006127503-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS AMGEN INC (US) 2006-11-30 WO claimed